Search

Unlocking the immunology of whooping cough vaccines to guide the development of improved vaccines and schedules in Australia

Ruth Peter Thornton Richmond PhD MBBS MRCP(UK) FRACP Co-head, Bacterial Respiratory Infectious Disease Group (BRIDG) Head, Vaccine Trials Group

World-first nasal spray whooping cough vaccine aims to protect young bubs

Tiny babies could soon have much-needed protection from community transmission of potentially deadly whooping cough thanks to a world-first nasal spray vaccine being trialed at The Kids Research Institute Australia.

The Kids Research Institute Australia research ensures kids are protected against whooping cough

Research by The Kids Research Institute Australia will soon ensure young children are better protected against whooping cough.

Immunisation

Immunisation is the most effective way of protecting your child against a range of serious illnesses, including measles, hepatitis B and whooping cough. All vaccines used in Australia undergo stringent testing and ongoing monitoring.

Extra whooping cough shots to protect bubs

An extra whooping cough vaccination for babies comes as a result of work by researchers at the Wesfarmers Centre of Vaccines and Infectious Diseases.

Antibody and cell-mediated immunity to pertussis 4 years after monovalent acellular pertussis vaccine at birth

In the longest reported follow-up of infants who received aP vaccine at birth, we found a trend to lower PT IgG antibodies post booster compared with receipt...

Predictors of Disease Severity in Children Hospitalized for Pertussis during an Epidemic

This study aimed to determine factors associated with severe pertussis in hospitalized children during an epidemic using a novel pertussis severity scoring...

Duration of protection after first dose of acellular pertussis vaccine in infants

Without a booster dose, the effectiveness of 3 doses waned more rapidly from 2 to 4 years of age than previously documented for children >6 years of age who...

Whither pertussis?

This article discusses the rising prevalence of pertussis disease in countries which have switched to acellular vaccines.

An observational study of antibody responses to a primary or subsequent pertussis booster vaccination in Australian healthcare workers

Adult pertussis vaccination is increasingly recommended to control pertussis in the community. However, there is little data on the duration and kinetics of immunity to pertussis boosters in adults. We compared IgG responses to vaccination with a tetanus, low-dose diphtheria, low-dose acellular pertussis (Tdap) booster at 1 week, 1 month and 1 year post-vaccination in whole-cell (wP)-primed Australian paediatric healthcare workers who had received an adult Tdap booster 5-12 years previously, to those who received their first Tdap booster. Tdap vaccination was well tolerated in both groups.